| (Values in U.S. Thousands) | Feb, 2026 | Feb, 2026 | Feb, 2026 | Feb, 2026 | Feb, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Cybrdi Inc (CYDI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cybrdi Inc was incorporated on August 1, 1966, under the laws of the State of California. It is a holding company, engaged in biotechnology manufacturing, research and development. The company manufactures both human and animal tissue micro-array for various scientific uses, including drug discovery and development. The company tissue microarrays technology surveys clinical specimens in a single experiment utilizing common probes, including DNA, RNA, peptide, protein and antibody probes. The Company through Chaoying Biotech, controls SD Chaoying, a cultural and entertainment company. There are two primary regions in China where the Company focus its marketing: the northern provinces which include the cities of Beijing, Tianjing and Hebei Province, and the eastern provinces which include the cities of Shanghai, Jiangsu , Guangdong, Fujian, Shaanxi, Hunan, Hubei, Zhejiang Province and Shandong Province. Currently, its owns four invention patents: ZL01128783.7, ZL01131756.6, ZL02415561.9 and ZL02145535.X.
Fiscal Year End Date: 12/31